Physical activity, body fat, and serum C-reactive protein in postmenopausal women with and without hormone replacement

American Journal of Human Biology

Volumn 15, Issue 1, 2003, Pages 91-100

  Manns, Patricia J ^a   Williams, Daniel P ^b   Snow, Christine M ^a   Wander, Rosemary C ^c  

^a OREGON STATE UNIVERSITY   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; C REACTIVE PROTEIN; CHOLESTEROL; CONJUGATED ESTROGEN; CORTICOSTEROID; FIBRIC ACID DERIVATIVE; GESTAGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRIACYLGLYCEROL;

ADULT; AGED; ALCOHOL CONSUMPTION; ANTHROPOMETRY; ARTICLE; BODY FAT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG USE; DUAL ENERGY X RAY ABSORPTIOMETRY; ENERGY EXPENDITURE; FEMALE; GLUCOSE BLOOD LEVEL; HORMONAL THERAPY; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MULTIVARIATE ANALYSIS; OBESITY; OUTCOMES RESEARCH; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOSE TISSUE; AGED; BODY COMPOSITION; C-REACTIVE PROTEIN; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; MOTOR ACTIVITY; POSTMENOPAUSE;

EID: 0037239436     PISSN: 10420533     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajhb.10117     Document Type: Article

References (46)

1. Ainsworth BE, Haskell WL, Leon AS, Jacobs DR Jr, Montoye HJ, Sallis JF, Paffenbarger RS Jr. 1993. Compendium of physical activities: classification of energy costs of human physical activities. Med Sci Sports Exerc 25:71-80.
2. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. 1974. Enzymatic determination of total serum cholesterol. Clin Chem 20:470-475.
3. Assmann G, Schriewer H, Schmitz G, Hagele EO. 1983. Quantification of high-density-lipoprotein cholesterol by precipitation with phosphotungstic acid/MgCl2. Clin Chem 29:2026-2030.
4. Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, Vidal H, Hainque B. 2000. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 85:3338-3342.
5. Brett KM, Madans JH. 1997. Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. Am J Epidemiol 145:536-545.
6. Chenillot O, Henny J, Steinmetz J, Herbeth B, Wagner C, Siest G. 2000. High sensitivity C-reactive protein: biological variations and reference limits. Clin Chem Lab Med 38:1003-1011.
7. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, Sakkinen PA, Tracy RP. 1999a. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 100:717-722.
8. Cushman M, Meilahn EN, Psaty BM, Kuller LH, Dobs AS, Tracy RP. 1999b. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol 19:893-899.
9. Espeland MA, Stefanick ML, Kritz-Silverstein D, Fineberg SE, Waclawiw MA, James MK, Greendale GA. 1997. Effect of postmenopausal hormone therapy on body weight and waist and hip girths. Postmenopausal Estrogen-Progestin Interventions Study Investigators. J Clin Endocrinol Metab 82:1549-1556.
10. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. 2000. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102:42-47.
11. Fletcher SW, Colditz GA. 2002. Failure of estrogen plus progestin therapy for prevention. JAMA 288:366-367.
12. Freidwald WT, Levy RI, Fredrickson DS. 1972. Estimation of the concentration of low density lipoprotein cholesterol in plasma, with the use of the preparative ultracentrifuge. Clin Chem 18:499-502.
13. Frohlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, Muche R, Brenner H, Koenig W. 2000. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 23:1835-1839.
14. Gabay C, Kushner I. 1999. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448-454.
15. Gambacciani M, Ciaponi M, Cappagli B, Piaggesi L, De Simone L, Orlandi R, Genazzani AR. 1997. Body weight, body fat distribution, and hormonal replacement therapy in early postmenopausal women. J Clin Endocrinol Metab 82:414-417.
16. Geffken DF, Cushman M, Burke GL, Polak JF, Sakkinen PA, Tracy RP. 2001. Association between physical activity and markers of inflammation in a healthy elderly population. Am J Epidemiol 153: 242-250.
17. Going S, Williams D, Lohman T. 1995. Aging and body composition: biological changes and methodological issues. Exerc Sport Sci Rev 23:411-458.
18. Heinrich PC, Castell JV, Andus T. 1990. Interleukin-6 and the acute phase response. Biochem J 265:621-636.
19. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. 1998. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280:605-613.
20. Hutchinson WL, Koenig W, Frohlich M, Sund M, Lowe GD, Pepys MB. 2000. Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin Chem 46:934-938.
21. Imhof A, Froehlich M, Brenner H, Boeing H, Pepys MB, Koenig W. 2001. Effect of alcohol consumption on systemic markers of inflammation. Lancet 357: 763-767.
22. LaMonte MJ, Durstine JL, Yanowitz FG, Lim T, DuBose KD, Davis P, Ainsworth BE. 2002. Cardiorespiratory fitness and c-reactive protein among a tri-ethnic sample of women. Circulation 106:403-406.
23. Lee IM, Rexrode KM, Cook NR, Manson JE, Buring JE. 2001. Physical activity and coronary heart disease in women: is "no pain, no gain" passe? JAMA 285: 1447-1454.
24. Lohman TG, Roche AF, Martorell R. 1988. Anthropometric standardization manual. Champaign, IL: Human Kinetics.
25. Mattusch F, Dufaux B, Heine O, Mertens I, Rost R. 2000. Reduction of the plasma concentration of C-reactive protein following nine months of endurance training. Int J Sports Med 21:21-24.
26. McGowan MW, Artiss JD, Strandbergh DR, Zak B. 1983. A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin Chem 29:538-542.
27. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW. 1997. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82:4196-4200.
28. National Institutes of Health/National Heart Lung and Blood Institute. 1998. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. The evidence report. Obes Res 6:51S-209S.
29. Pasceri V, Willerson JT, Yeh ET. 2000. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102:2165-2168.
30. Pate RR, Pratt M, Blair SN, Haskell WL, Macera CA, Bouchard C, Buchner D, Ettinger W, Heath GW, King AC, et al. 1995. Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine [see Comments]. JAMA 273:402-407.
31. Pietrobelli A, Formica C, Wang Z, Heymsfield SB. 1996. Dual-energy X-ray absorptiometry body composition model: review of physical concepts. Am J Physiol 271:E941-E951.
32. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. 1997. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men [see Comments]. N Engl J Med 336:973-979 [erratum N Engl J Med 1997 31;337(5):356].
33. Ridker PM, Glynn RJ, Hennekens CH. 1998. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction [see Comments]. Circulation 97: 2007-2011.
34. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. 1999. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 100:713-716.
35. Ridker PM, Hennekens CH, Buring JE, Rifai N. 2000. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342:836-843.
36. Sallis JF, Haskell WL, Wood PD, Fortmann SP, Rogers T, Blair SN, Paffenbarger RS Jr. 1985. Physical activity assessment methodology in the Five-City Project. Am J Epidemiol 121:91-106.
37. Smith JK, Dykes R, Douglas JE, Krishnaswamy G, Berk S. 1999. Long-term exercise and atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease. JAMA 281: 1722-1727.
38. Smith SC Jr, Greenland P, Grundy SM. 2000. AHA Conference Proceedings. Prevention conference V: beyond secondary prevention: identifying the high-risk patient for primary prevention: executive summary. American Heart Association. Circulation 101:111-116.
39. Sowers MF, Crutchfield M, Jannausch ML, Russell-Aulet M. 1996. Longitudinal changes in body composition in women approaching the midlife. Ann Hum Biol 23:253-265.
40. Taaffe DR, Harris TB, Ferrucci L, Rowe J, Seeman TE. 2000. Cross-sectional and prospective relationships of interleukin-6 and C-reactive protein with physical performance in elderly persons: MacArthur studies of successful aging. J Gerontol A Biol Sci Med Sci 55: M709-M715.
41. Tchernof A, Nolan A, Sites CK, Ades PA, Poehlman ET. 2002. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 105: 564-569.
42. Torzewski M, Rist C, Mortensen RF, Zwaka TP, Bienek M, Waltenberger J, Koenig W, Schmitz G, Hombach V, Torzewski J. 2000. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 20:2094-2099.
43. Trinder P. 1969. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem 6:24-27.
44. Writing Group for the PEPI Trial. 1995. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 273:199-208.
45. Writing Group for the Women's Health Initiative Investigators. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333.
46. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. 2000. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148:209-214.